SHLT vs. TOI, CCM, HIMS, TDOC, AUNA, SBC, AIRS, LFMD, CHRS, and INFU
Should you be buying SHL Telemedicine stock or one of its competitors? The main competitors of SHL Telemedicine include Oncology Institute (TOI), Concord Medical Services (CCM), Hims & Hers Health (HIMS), Teladoc Health (TDOC), Auna (AUNA), SBC Medical Group (SBC), AirSculpt Technologies (AIRS), LifeMD (LFMD), Coherus BioSciences (CHRS), and InfuSystem (INFU).
SHL Telemedicine vs.
Oncology Institute (NASDAQ:TOI) and SHL Telemedicine (NASDAQ:SHLT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.
SHL Telemedicine has a net margin of 0.00% compared to Oncology Institute's net margin of -17.63%. SHL Telemedicine's return on equity of 0.00% beat Oncology Institute's return on equity.
36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 20.1% of SHL Telemedicine shares are owned by institutional investors. 9.5% of Oncology Institute shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Oncology Institute has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, SHL Telemedicine has a beta of -0.3, indicating that its stock price is 130% less volatile than the S&P 500.
SHL Telemedicine has lower revenue, but higher earnings than Oncology Institute.
In the previous week, SHL Telemedicine's average media sentiment score of 0.00 beat Oncology Institute's score of -0.36 indicating that SHL Telemedicine is being referred to more favorably in the news media.
Oncology Institute received 3 more outperform votes than SHL Telemedicine when rated by MarketBeat users. However, 100.00% of users gave SHL Telemedicine an outperform vote while only 66.67% of users gave Oncology Institute an outperform vote.
Oncology Institute presently has a consensus price target of $2.50, indicating a potential upside of 317.85%. SHL Telemedicine has a consensus price target of $11.00, indicating a potential upside of 285.96%. Given Oncology Institute's higher probable upside, analysts plainly believe Oncology Institute is more favorable than SHL Telemedicine.
Summary
Oncology Institute and SHL Telemedicine tied by winning 6 of the 12 factors compared between the two stocks.
Get SHL Telemedicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for SHLT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
SHL Telemedicine Competitors List
Related Companies and Tools
This page (NASDAQ:SHLT) was last updated on 1/22/2025 by MarketBeat.com Staff